By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Infinity Pharmaceuticals Inc. 

780 Memorial Drive

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-453-1000 Fax: 617-453-1001

The mission of Infinity Pharmaceuticals, Inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation.

Small molecule discovery and development capabilities
Infinity’s programs arise from the integration of a broad range of research and development capabilities, including strengths in cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation.

Strategic alliances
Building on its strengths in innovative small molecule drug discovery and development, Infinity has established significant alliances with leading pharmaceutical and biotechnology companies to help realize the full potential of its product pipeline.

Business and scientific expertise
The company has assembled a team of passionate, committed, and innovative individuals who bring together their collective expertise in all areas of business and drug discovery and development.

Culture of Citizen-Ownership
Infinity’s culture and environment of Citizen-Ownership is as important as its technologies. Infinity works together as a community with the shared goal of bringing important new medicines to patients.

Key Statistics

Ownership: Public

Web Site: Infinity Pharmaceuticals Inc.
Employees: 180
Symbol: INFI



Company News
Infinity Pharmaceuticals Inc. (INFI) Provides Key 2016 Goals And Financial Guidance 1/11/2016 11:30:23 AM
Infinity Pharmaceuticals Inc. (INFI) To Present At J.P. Morgan Annual Healthcare Conference 1/6/2016 10:59:43 AM
Medidata’s Risk-Based Monitoring Solution Selected By Infinity Pharmaceuticals Inc. (INFI) To Advance Oncology Research 11/24/2015 12:25:29 PM
Infinity Pharmaceuticals Inc. (INFI) Announces Completion Of Target Enrollment In DUO, A Phase 3 Study Evaluating duvelisib In Chronic Lymphocytic Leukemia 11/17/2015 7:17:49 AM
Infinity Pharmaceuticals Inc. (INFI) Provides Company Update And Reports Third Quarter 2015 Financial Results 11/6/2015 6:56:49 AM
Infinity Pharmaceuticals Inc. (INFI) Announces The Date Of Its Third Quarter 2015 Financial Results Conference Call And Webcast 10/28/2015 11:32:32 AM
Infinity Pharmaceuticals Inc. (INFI) To Provide Update On Duvelisib And Immuno-Oncology Development Candidate IPI-549 During 2015 Research And Development Day 10/6/2015 6:36:58 AM
Infinity Pharmaceuticals Inc. (INFI) Announces Enrollment Of 120th Patient In Phase 2 DYNAMO Study Evaluating Duvelisib In Indolent Non-Hodgkin Lymphoma 9/30/2015 7:22:54 AM
Lead Discovery Center And Infinity Pharmaceuticals Inc. (INFI) To Cooperate On The Identification Of Novel Drug Discovery And Development Opportunities In Oncology 9/29/2015 10:02:20 AM
Infinity Pharmaceuticals Inc. (INFI) To Host 2015 Research & Development Day 9/22/2015 10:43:50 AM